✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Best HIV Treatment Regimens in 2026: 10 Evidence-Backed Antiretroviral Picks

The treatment of HIV has been transformed in the past 30 years. Three-drug single-tablet regimens taken once daily now suppress viral load to undetectable in >95% of patients within 6 months, restore CD4 counts to near-normal, and confer normal life expectancy when started early. The central concept is “U=U” (undetectable equals untransmittable) — a person on effective ART with sustained viral suppression cannot transmit HIV sexually.

This guide ranks the 10 antiretroviral medications most worth knowing about in 2026. The mix covers fixed-dose first-line three-drug combinations, second-line and salvage regimens, and individual integrase inhibitors used in optimised backbone regimens. Each pick links to a full product page; the comparison table shows backbone and best-fit indication. For PrEP (prevention) the canonical picks are in our dedicated PrEP medications hub.

• Table of Contents

  • How modern ART works
  • The 10 picks (ranked)
  • Comparison table
  • Decision shortcut
  • Safety, monitoring, and resistance
  • PrEP and PEP context
  • FAQs
  • Bottom line

How modern ART works

Antiretroviral therapy targets multiple steps in the HIV replication cycle. A modern first-line regimen always combines drugs from at least two different classes, to prevent resistance:

• NRTIs (nucleoside / nucleotide reverse transcriptase inhibitors) — tenofovir (TDF or TAF), emtricitabine (FTC), lamivudine (3TC), zidovudine (ZDV), abacavir (ABC). Block reverse transcriptase. Form the “backbone” of most regimens.
• NNRTIs (non-nucleoside reverse transcriptase inhibitors) — efavirenz (EFV), nevirapine, rilpivirine, doravirine. Bind reverse transcriptase at a different site. EFV is the most-used NNRTI in WHO first-line regimens worldwide.
• INSTIs (integrase strand transfer inhibitors) — dolutegravir (DTG), raltegravir, elvitegravir, bictegravir. Block integration of viral DNA into the host genome. Highest genetic barrier to resistance of any class; preferred third agent in current guidelines.
• Protease inhibitors (PIs) — lopinavir, atazanavir, darunavir, ritonavir (booster). Block viral protease. Less commonly used in first-line modern regimens but remain important in salvage / treatment-experienced populations.

The optimal first-line regimen for most people in 2026 is 2 NRTIs + 1 INSTI — specifically TDF or TAF + FTC or 3TC + dolutegravir or bictegravir — because of the combination’s tolerability, once-daily single-tablet convenience, and very high genetic barrier to resistance.

The 10 picks (ranked)

1. Trioday (TDF 300 + 3TC 300 + EFV 600) — the WHO-recommended global first-line ART

Trioday is the single-tablet, once-daily three-drug regimen used by the majority of people on first-line ART worldwide — tenofovir disoproxil fumarate 300 mg + lamivudine 300 mg + efavirenz 600 mg. WHO guidelines have endorsed this combination for >15 years; it’s the lowest-cost effective first-line regimen and remains widely used in resource-limited settings. The efavirenz component causes vivid dreams and dizziness in the first 2–4 weeks (take at bedtime), which usually settles. Avoid in pregnancy planning (small first-trimester teratogenicity signal — dolutegravir-based Avonza is preferred when pregnancy is possible). Buy Trioday.

2. Avonza (TDF 300 + 3TC 300 + DTG 50) — the WHO-recommended modern first-line ART

Avonza replaces the efavirenz in Trioday with dolutegravir — an integrase inhibitor with better tolerability, faster viral load suppression, and a much higher genetic barrier to resistance. Side-effect profile is cleaner than efavirenz (no neuropsychiatric effects, no D:A:D-style cardiovascular signals). The 2026 WHO update positions a TDF + 3TC or FTC + DTG combination as first-line for adults and adolescents in most settings; Avonza is the standard local manifestation. The historical concern about DTG and neural-tube defects from the Tsepamo cohort has been substantially attenuated by larger follow-up data and DTG is now considered safe in pregnancy (and actually preferred). Buy Avonza.

3. Tenvir EM (TDF 300 + FTC 200) — the most-used NRTI backbone, also the global PrEP standard

Tenvir EM is the two-drug NRTI backbone (tenofovir disoproxil + emtricitabine) used in countless three-drug regimens and as the PrEP standard. As a backbone, it’s combined with an INSTI, NNRTI, or PI to form a complete regimen (e.g., Tenvir EM + dolutegravir = the same as Avonza but in two pills, useful for dose adjustment in renal impairment). As PrEP, it’s taken once daily by HIV-negative individuals at risk of exposure (full PrEP guidance is in the PrEP hub). Buy Tenvir EM.

4. Ricovir EM (TDF 300 + FTC 200, Mylan brand) — bioequivalent Mylan brand of TDF + FTC backbone

Ricovir EM is the Mylan brand of the TDF + FTC backbone — same molecules, same dosing as Tenvir EM. Choice between Ricovir EM and Tenvir EM comes down to availability and pricing. Both are widely used as first-line backbone in three-drug regimens and as PrEP. Buy Ricovir EM.

5. Tenvir AF (TAF 25 + FTC 200) — the kidney-friendly and bone-friendly alternative to TDF backbone

Tenofovir alafenamide (TAF) is a prodrug of tenofovir that produces ~90% lower plasma tenofovir levels but equivalent intracellular drug levels — meaning the same antiviral activity with significantly less renal tubular toxicity and bone-mineral-density loss. Tenvir AF is the right backbone for patients with eGFR <60, established CKD, osteopenia or osteoporosis, or anyone who’s been on TDF for >5 years and would benefit from a switch. The trade-off is modest: TAF causes ~2–3 kg weight gain over 2 years vs TDF, and lipid profiles trend slightly worse on TAF. Buy Tenvir AF.

6. Zepdon (dolutegravir 50 mg) — the standalone INSTI for optimised regimens

Zepdon is dolutegravir 50 mg as a single agent — used when the patient needs a custom regimen rather than the fixed-dose Avonza. Common scenarios: TAF-based backbone (Tenvir AF + Zepdon for renal/bone protection), pregnancy switch from EFV-based to DTG-based, treatment-experienced patient with renal dosing adjustments needed for the NRTI backbone. Once-daily dosing; well-tolerated. Take 2 hours apart from antacids and iron / calcium supplements (cation chelation reduces absorption). Buy Zepdon.

7. Isentress (raltegravir 400 mg) — the original integrase inhibitor, still used in salvage and renal-impaired patients

Raltegravir is the first INSTI to market (2007) and remains useful in treatment-experienced patients with INSTI-resistant virus, in renal failure (no dose adjustment needed because of hepatic metabolism), and as part of triple-class salvage regimens. The 400 mg twice daily dosing is less convenient than once-daily DTG, and the genetic barrier to resistance is lower — so raltegravir is rarely chosen as first-line in 2026, but it remains an essential salvage option. Buy Isentress.

8. Instgra (dolutegravir 50 mg, alt brand) — alternative dolutegravir brand for cost-sensitive prescribing

Instgra is an alternative brand of dolutegravir 50 mg. Therapeutically identical to Zepdon. The choice between alternative DTG brands is driven by cost and supply availability rather than clinical difference. Buy Instgra.

9. Ritocom (lopinavir 200 + ritonavir 50) — the legacy boosted PI for second-line and salvage

Lopinavir/ritonavir (LPV/r) is a boosted protease inhibitor used in second-line regimens after first-line failure of an NNRTI- or INSTI-based regimen. Twice-daily dosing, GI side effects (diarrhoea is common), significant lipid disturbance with chronic use, and many drug interactions (CYP3A4 inhibition is strong). Largely replaced by darunavir/cobicistat in resource-rich settings, but still used worldwide for cost reasons in second-line. Also one of the few options in some treatment-failure scenarios. Buy Ritocom.

10. Triomune (D4T 30 + 3TC 150 + NVP 200) — the legacy first-line, kept for context, switch to TDF-based if possible

Triomune (stavudine + lamivudine + nevirapine) is the legacy first-line ART that was widely used in resource-limited settings before tenofovir became affordable. It’s included here for transparency and for patients who are still taking it and need to know the current recommendation is to switch. The standard switch is to Trioday (TDF + 3TC + EFV) or Avonza (TDF + 3TC + DTG), supervised by an HIV specialist. Triomune product page.

Comparison table

Safety, monitoring, and resistance

Standard monitoring on first-line ART:

• Baseline: HIV RNA viral load, CD4 count, HLA-B*5701 (if abacavir use planned), HBsAg + HCV serology, full chemistry + LFTs + renal panel + lipids, pregnancy test, resistance testing if available.
• 2 weeks: clinical review, side effect check.
• 4 weeks: viral load (should be dropping), renal function (TDF), liver function (NNRTI / DTG).
• 3 months: viral load (target <200 copies/mL), CD4, renal, liver, lipids.
• 6 months: viral load (target <50 copies/mL = undetectable), then every 6–12 months once stable.

Resistance is the primary risk of non-adherence. Missing >5% of doses (about 1 dose per week) over weeks-to-months allows the virus to develop resistance mutations — particularly to NNRTIs (low genetic barrier), less so to INSTIs (high barrier with DTG). Once resistance to a class develops, future regimens become more expensive, more complex, and more side-effect-prone. The single most important intervention to prevent resistance is to support adherence through reminder systems, pill organisers, simplified once-daily regimens (Avonza, Trioday), and rapid management of side effects that drive discontinuation.

Drug interactions worth flagging:

• Dolutegravir (Zepdon, in Avonza) and raltegravir (Isentress) chelate with metal cations — take 2 hours apart from antacids, iron, calcium, magnesium supplements.
• Efavirenz (in Trioday) is a CYP3A4 inducer — reduces levels of methadone, hormonal contraceptives (use barrier or IUD), warfarin, statins.
• Ritonavir (in Ritocom) is a strong CYP3A4 inhibitor — increases levels of statins (lovastatin and simvastatin contraindicated), midazolam, ergot alkaloids, fentanyl, sildenafil.
• Tenofovir + NSAIDs — additive renal toxicity; minimise chronic NSAID use on TDF; switch to TAF if NSAIDs are needed long-term.

PrEP and PEP context

This hub covers treatment regimens for people with diagnosed HIV. Two related but distinct interventions are sometimes confused:

• PrEP (pre-exposure prophylaxis) — HIV-negative individuals at risk of exposure take a daily TDF/FTC tablet (Tenvir EM, Ricovir EM) to prevent infection. Reduces sexual HIV acquisition by >99% with consistent adherence. Full picks list and regimen options are in the PrEP medications hub.
• PEP (post-exposure prophylaxis) — for HIV-negative individuals after a single high-risk exposure (occupational needlestick, condomless sex with positive partner, sexual assault). 28-day course of three-drug ART, started ideally within 2 hours and no later than 72 hours post-exposure. Standard PEP regimen is TDF + FTC + DTG (effectively a 28-day course of Avonza).

If you’re looking for prevention rather than treatment, jump to the PrEP hub for the dedicated picks list.

Frequently Asked Questions

What does “undetectable equals untransmittable” (U=U) mean?

People with HIV who maintain a fully suppressed viral load (<200 copies/mL on standard testing, sustained for ≥6 months) on effective ART cannot transmit HIV through sexual contact. This is supported by overwhelming evidence from the PARTNER and Opposites Attract studies among others. U=U is the single most important practical reframing of HIV in the past decade — effective treatment is also effective prevention. It does not eliminate transmission via blood-to-blood contact (sharing injection equipment, vertical transmission without ART), but for sexual transmission, U=U holds.

Why is dolutegravir-based ART preferred over efavirenz-based?

Three reasons: (1) better tolerability — no neuropsychiatric side effects (vivid dreams, dizziness, depression risk), no first-2-week adjustment phase, (2) higher genetic barrier to resistance — INSTIs require multiple mutations to develop clinically meaningful resistance, vs single-mutation resistance with NNRTIs, (3) faster viral suppression — DTG-based regimens reach undetectable status weeks faster than EFV-based. The trade-off is cost; DTG-based regimens are more expensive than EFV-based, which is why Trioday remains widely used in resource-limited settings.

When should I switch from TDF to TAF?

If you have eGFR <60, established CKD, osteopenia or osteoporosis, or have been on TDF for >5–10 years and are starting to show kidney or bone signal, switching to TAF (Tenvir AF) reduces renal and bone toxicity significantly. The trade-off is ~2–3 kg weight gain over 2 years on TAF and slightly worse lipid profiles. For most patients with normal kidneys and bones, TDF (Trioday, Avonza, Tenvir EM) remains a reasonable choice for long-term first-line.

Is HIV treatment lifelong?

Yes. Current ART suppresses viral replication but does not eliminate the latent HIV reservoir in long-lived cells (memory CD4 T cells, macrophages). Stopping ART almost always leads to viral rebound within weeks. Cure research (latency-reversal agents, broadly neutralising antibodies, gene therapy) is active but no widely available cure exists in 2026. The practical implication: planning for lifelong adherence, including for people who feel completely well, is essential.

Can I take ART during pregnancy?

Yes — ART during pregnancy reduces vertical (mother-to-child) transmission from ~25% to <1%. The 2026 preferred regimen is dolutegravir-based (Avonza) for both treatment and PrEP in pregnancy. Earlier concerns about a small DTG-related neural-tube-defect signal (Tsepamo cohort) have been substantially attenuated by larger follow-up data. Efavirenz-based Trioday is still acceptable, but DTG-based is preferred.

What does “resistance” actually mean?

HIV mutates rapidly during replication. When ART partially suppresses but doesn’t fully eliminate replication (the “sub-therapeutic” window during missed doses), resistant viral variants emerge that the current drugs can’t suppress. The virus continues replicating in the presence of the drug, viral load rises, and the regimen fails. Resistance to one drug in a class often confers cross-resistance to other drugs in the same class. Once resistance develops, the patient needs a new regimen with at least 2 fully-active drugs from different classes — harder, more expensive, more side-effects. The best prevention is consistent dosing.

Are HIV medications expensive?

Generic ART (manufactured in India and elsewhere) is dramatically more affordable than brand-name versions. Trioday and Avonza in generic form cost a fraction of what equivalent brand combinations cost in the US or EU. WHO and national HIV programs in many countries provide ART free at point of care.

What’s the difference between HIV and AIDS?

HIV is the virus; AIDS is the late-stage clinical syndrome that develops when CD4 counts fall below 200/µL or specific opportunistic infections appear. Modern ART started early prevents progression to AIDS in >95% of cases. People diagnosed with HIV in 2026 who start treatment promptly have near-normal life expectancy and never develop AIDS.

Bottom line

For first-line HIV treatment in 2026, the consensus pick is a single-tablet, once-daily, three-drug regimen of two NRTIs + one INSTI — Avonza (TDF + 3TC + DTG) is the modern standard. Trioday (TDF + 3TC + EFV) remains widely used for cost reasons and is fully effective with the caveat of efavirenz-related neuropsychiatric side effects in the first 2–4 weeks. Patients with kidney or bone concerns should switch to Tenvir AF backbone + Zepdon.

For salvage, Isentress + Ritocom + new NRTI backbone is the workhorse. Patients still on legacy Triomune (stavudine-based) should be switched to TDF-based first-line under specialist supervision.

The single most important practical point: HIV treatment is lifelong, and adherence is everything. Missed doses lead to resistance, which leads to limited future options. Choose the regimen that you can actually take every day — usually the once-daily single-tablet option even if it costs slightly more.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.